Review
Version 1
Preserved in Portico This version is not peer-reviewed
KRAS-Mutant Non–Small Cell Lung Cancer: Recent Progress
Version 1
: Received: 24 November 2021 / Approved: 26 November 2021 / Online: 26 November 2021 (11:34:27 CET)
How to cite: shu, C.; Liu, Y.; Zhou, C. KRAS-Mutant Non–Small Cell Lung Cancer: Recent Progress. Preprints 2021, 2021110504. https://doi.org/10.20944/preprints202111.0504.v1 shu, C.; Liu, Y.; Zhou, C. KRAS-Mutant Non–Small Cell Lung Cancer: Recent Progress. Preprints 2021, 2021110504. https://doi.org/10.20944/preprints202111.0504.v1
Abstract
The KRAS mutant population has been undruggable for 40 years. G12C inhibitors and immunotherapy are the beginning of success. It is necessary to summarize the successful experience of the existing treatment model and explore the direction of the next treatment. In this review, we discuss the latest developments in targeted therapy and immunotherapy for KRAS-mutation NSCLC, aiming to provide direction or enlightenment for future treatment strategies.
Keywords
NSCLC 1; KRAS G12C mutation 2; targeted therapy 3; immunotherapy 4
Subject
Biology and Life Sciences, Immunology and Microbiology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment